(Q44656502)

5 December 2017

Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure (English)

1 reference

5 December 2017

1 reference

7

1 reference

5 December 2017

Ana I Tergas

1

1 reference

5 December 2017

Rebecca Buell-Gutbrod

2

1 reference

5 December 2017

Katja Gwin

3

1 reference

5 December 2017

Masha Kocherginsky

4

1 reference

5 December 2017

Sarah M Temkin

5

1 reference

5 December 2017

Ann Fefferman

6

1 reference

5 December 2017

S Diane Yamada

8

1 reference

5 December 2017

language of work or name

English

0 references

publication date

24 July 2012

1 reference

5 December 2017

1 reference

5 December 2017

127

1 reference

5 December 2017

2

1 reference

5 December 2017

316-320

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Association of tamoxifen and uterine sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Uterine sarcoma associated with tamoxifen use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Pten, a protean tumor suppressor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

PTEN function in normal and neoplastic growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Tamoxifen therapy for breast cancer and endometrial cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Relationship between tamoxifen use and high risk endometrial cancer histologic types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Factors predictive of response to hormone therapy in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.105

10.1016/J.YGYNO.2012.07.105

7 January 2021

Identifiers

DOI

1 reference

release_tfkaoy3qrneufjxyqhhybpxntu

5 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tfkaoy3qrneufjxyqhhybpxntu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference